A Study to Evaluate Ethanol-induced Symptoms and Safety in Breast Cancer Patients
NCT ID: NCT06537752
Last Updated: 2025-09-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1052 participants
OBSERVATIONAL
2024-07-15
2026-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Complementary or Alternative Medicine Practices Used by Women at Increased Risk for Breast Cancer
NCT00020098
Aromatherapy in the Treatment of Early Breast Cancer
NCT06435104
Factors Correlated With Fatigue in Breast Cancer
NCT01064427
RESISTANCE VERSUS AEROBIC EXERCISES ON Breast Cancer Patients
NCT04656457
Nutrition, Exercise, and Breast Cancer Survivorship
NCT01151488
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Those are confirmed to have primary breast cancers through histological diagnosis and one of the following are applicable.
* Those who need neoadjuvant chemotherapy as breast cancer patients
* Those who need adjuvant chemotherapy after breast cancer surgery
* Those who are scheduled to administer non-ethanol formulation docetaxel according to chemotherapy
* Those able to understand this study, be cooperative in the execution of the study, and participate in the study until its completion.
Exclusion Criteria
* Those are diagnosed with secondary breast cancers.
* Those with Stage 0/1 (Tis, N0, M0) or Stage IV (any T, Any N, M1) breast cancers.
19 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boryung Pharmaceutical Co., Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chung-Ang University Hospital
Seoul, , South Korea
Uijeongbu Eulji Medical Center, Eulji University
Uijeongbu-si, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Min Kyoon Kim
Role: primary
Byung Joo Song
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BR-DTX-OS-402
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.